The guidelines provide updated recommendations for managing transfusion-dependent thalassemia (TDT), emphasizing regular blood transfusions, iron chelation therapy, and monitoring/management of various complications. They also highlight the importance of a multidisciplinary approach, patient-centered care, and addressing psychosocial aspects for optimizing quality of life in TDT patients.

AT reports consultancy fees, research funding, and speaker honoraria from several pharmaceutical companies. EY reports advisory board fees and speaker honoraria from pharmaceutical companies. The remaining authors declare no conflicts of interest.

These guidelines provide a comprehensive overview of managing transfusion-dependent thalassemia, covering diagnosis, treatment, and management of complications. Although relying heavily on expert consensus, they reflect the current best practices in the field. The inclusion of novel therapies and psychosocial considerations strengthens the guidelines. Points were deducted due to reliance on expert opinions and some gaps in robust, clinical study support.